Precursor Chemical Identification and Supply-Chain Evaluation (PRECISE)

Context

Drug reform policy was a hot-button issue in recent EU and US elections because of the proliferation of synthetic opioids. The EU reported approximately 1 million high-risk opioid users¹ and the US reported DEA seizures of fentanyl powder that nearly doubled in 2023, while the 79 million fentanyl pills seized nearly tripled². This crisis is predominantly fueled by the illicit dissemination of precursor chemicals. A significant portion of these precursors originate from China, fueling immense scrutiny from both the United States and the European Union. Specifically, the *EU-China Joint Meeting on Drug Precursors*³ and February 2025 U.S. Presidential Action⁴ both work to curb the synthetic opioid epidemic through checks on China. While both parties have worked to regulate the market through dialogue, AI-driven invoice regulation would directly secure supply chains and protect the legitimate EU-US pharmaceutical market.

Structure

PRECISE develops a shared AI invoice regulation tool between the United States and the European Union to track precursor chemical inventory. This tool will be integrated into e-invoices along the EU-US supply chain, similar to China's "E-Fapiao" system¹. The US and the EU will send delegates annually to track the progress and success of **PRECISE**.

Objectives


- 1. Prevent the proliferation of precursor chemicals to fentanyl from China.
- 2. Boost Transatlantic collaboration on AI development through private sector and academic channels.
- 3. Reform the Trade and Technology Council as a PPP framework to implement **PRECISE**.
- 4. Develop a framework for future collaboration on joint US-EU AI initiatives.

Implementation

- 1) Framework for the Development of **PRECISE**:
 - Recommends a joint fund of 150M-200M USD to create an innovation grant.
 - Establishes a bidding system available to the private sector and research institutions evaluated by working groups.
 - Requires the use of open-source models for development and data sharing between awardees.
 - Encourages cross-sector consultation to increase efficacy, including funding audit.

¹ Edicom Group. 2025. "E-Fapiao (fully digitalized E-Fapiao) in China: full adoption as of December 2024 | EDICOM Global." Edicom. https://edicomgroup.com/blog/china-moves-to-implement-the-electronic-invoice.

2



(U) FIGURE 1. FENTANYL FLOW TO THE UNITED STATES 2019

² European Union Drugs Agency (EUDA), Key Findings and Threat Assessment: Heroin and Other Opioids, accessed April 5, 2025,


https://www.euda.europa.eu/publications/eu-drug-markets/heroin-and-other-opioids/key-findings-and-threat-assessm ent_en.

^{2.} U.S. Drug Enforcement Administration, DEA Releases 2024 National Drug Threat Assessment, May 9, 2024, https://www.dea.gov/press-releases/2024/05/09/dea-releases-2024-national-drug-threat-assessment.


^{3.}European Parliament, Answer Given by Ms Johansson on Behalf of the European Commission (E-001815/2024), April 2024, <u>https://www.europarl.europa.eu/doceo/document/E-10-2024-001815-ASW_EN.html#def9</u>.

^{4.} The White House, Imposing Duties to Address the Synthetic Opioid Supply Chain in the People's Republic of China, February 2025,


https://www.whitehouse.gov/presidential-actions/2025/02/imposing-duties-to-address-the-synthetic-opioid-supply-c hain-in-the-peoples-republic-of-china/.



Main EU partners for medicinal and pharmaceutical products, 2023 (%)



Source: Eurostat (online data code: DS-059331)



Exports

eurostat <